Competitive Intelligence for Contract Research Organizations

Contract research organizations (CROs) win oncology work by understanding a sponsor’s science as well as its operations. A bid that shows command of the competitive landscape, from rival programs to the evolving standard of care, signals that the team can design and run a trial that survives contact with reality. Competitive intelligence (CI) for contract research organizations is how CRO teams build that command. For a service overview, see Oncology Resource Group’s page for contract research organizations.

Updated October 8, 2026.

What sponsors are running, and why it matters to a CRO

Trial design in oncology is shifting in ways that change feasibility, timelines and site strategy. The examples below, all from the past 18 months, show patterns CRO teams should recognize.

• Noninferiority and bridging designs are common. Merck’s subcutaneous pembrolizumab was approved on September 19, 2025 based on Study MK-3475A-D77, a 377-patient NSCLC study comparing a subcutaneous with an IV formulation (FDA). Subcutaneous nivolumab was approved on a CheckMate-67T noninferiority basis (PearceIP). Pharmacokinetic bridging is now a standard lifecycle tool.
• Noninferiority also applies to treatment strategy. The CLL17 trial (909 patients) tested fixed-duration venetoclax regimens against continuous ibrutinib for three-year progression-free survival (OncLive). BRUIN CLL-314 compared pirtobrutinib with ibrutinib using a noninferiority response-rate endpoint (Oncology Nursing News).
• Endpoints keep evolving. In the CEPHEUS trial of Darzalex Faspro plus VRd, MRD negativity (52.3% vs 34.8% at a median 22 months) supported the January 27, 2026 FDA approval alongside a progression-free survival result (J&J). ctDNA now guides treatment selection: the May 15, 2026 adjuvant Tecentriq approval in bladder cancer was based on IMvigor011 in 250 ctDNA-positive patients (ONS Voice).
• Several sponsors are chasing the same comparator. Trials of newer bispecific antibodies against pembrolizumab-based regimens in first-line NSCLC are running in parallel (HARMONi-3, HARMONi-7, ROSETTA Lung-202 and Symbiotic-Lung-01) (BioNTech 6-K; Summit Q2 report). That is a feasibility question: how many sites and patients can support them all?
• Large programs launch. ClinicalTrials.gov lists four saruparib (PARP1-selective) Phase 3 trials, including EvoPAR-Prostate01 with 1,898 participants and an estimated primary completion of September 30, 2027 (ClinicalTrials.gov), and Regeneron’s REGN7508 has two Phase 3 cancer-associated thrombosis trials with estimated enrollments of 1,120 and 1,600 (ClinicalTrials.gov).
• Programs get cut. Both Phase 3 abelacimab cancer-associated thrombosis trials, with 1,150 and 417 participants enrolled, were terminated by the sponsor in early 2026 (ClinicalTrials.gov). Roche discontinued tiragolumab in July 2025 (ApexOnco), and AstraZeneca decided not to file its DUO-O combination in first-line ovarian cancer (AstraZeneca 6-K).
• Capital moves programs. BMS and BioNTech announced a partnership on the PD-L1/VEGF bispecific pumitamig in June 2025 with $1.5 billion upfront (DCAT), and Gilead announced the acquisition of Arcellx on February 23, 2026 at an implied equity value of $7.8 billion (Kite/Gilead). Deals shift which sponsors are hiring.

Where CI changes outcomes for a CRO

1. Proposals and bid defenses. Showing that you understand the sponsor’s competitors, comparator choices and likely enrollment challenges signals oncology depth.
2. Early-phase strategy. Novel mechanisms, biomarkers and shifting scientific paradigms inform how a first-in-human or proof-of-concept program should be structured.
3. Trial design and feasibility. Evolving standards of care, competing trials and endpoint precedents affect eligibility, sample size and timelines.
4. Site strategy. Knowing where competing studies are enrolling, and which centers have the diagnostics and capabilities a trial needs, shapes site selection.
5. Regulatory planning. Recent approvals, label narrowing and review outcomes set precedent for what regulators accept.

What a CRO-focused CI program should cover

• Sponsor intelligence: pipelines, recent data, deals and strategic priorities of current and prospective clients. See our guide to pipeline tracking.
• Landscape and trial histories: cancer-area-specific treatment and trial landscapes, including hard-to-find drug and trial histories. See treatment algorithm maps.
• Conference intelligence: what sponsors presented and how it shifts their next trial. See conference coverage. Upcoming meetings include ESMO (October 23-27, 2026) and ASH (December 12-15, 2026).
• Competitor and regulatory surveillance: trial starts, terminations, filings and approvals.

Specialized CROs and SMOs versus full-service firms

Global full-service CROs compete on scale and breadth, so their CI needs tend to focus on sponsor relationships across many programs. Scientific and specialized CROs and site management organizations compete on insight. For them, an accurate view of emerging biomarkers, rare tumor types or novel modalities can be the difference between being a vendor and being a scientific partner.

Building a program that works

1. Start with revenue decisions. Identify the bids, renewals and capacity decisions in the next year and the intelligence each needs.
2. Assign owners by cancer area. Depth beats breadth.
3. Label confidence. Distinguish registry data, regulator documents, peer-reviewed results and company claims, and say what is unconfirmed.
4. Keep a catalyst calendar. FDA action dates, congress dates and registry completions turn surveillance into planning.
5. Package for proposals. A reusable, updated landscape slide for each priority indication saves time when a bid arrives.

Common pitfalls

• Confusing an estimate with a plan. Registry start and completion dates are estimates and change.
• Quoting toplines as results. Sponsors often announce success before releasing numbers.
• Missing the negative signals. Terminations and decisions not to file tell you where a sponsor’s priorities have moved.

Next step

If your team wants stronger oncology intelligence for sponsor discussions, proposals and trial feasibility, Oncology Resource Group describes its approach for contract research organizations here: Oncology Resource Group: Contract Research Organizations. You can also request information from us directly.

Keep reading: competitive intelligence for pharmaceutical biotech, competitive intelligence for CROs and cancer centers and what is oncology competitive intelligence.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.